Abattis Bioceuticals (ATTBF) Stock Statistics & Valuation Metrics

Abattis Bioceuticals has a market cap or net worth of $478.00. The enterprise value is ―.

Abattis Bioceuticals has 477,804,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Abattis Bioceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Abattis Bioceuticals is ―. Abattis Bioceuticals’s PEG ratio is ―.

In the last 12 months, Abattis Bioceuticals had revenue of 356.88K and earned -3.04M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was 9.41M and capital expenditures -5.06M, giving a free cash flow of 4.35M billion.

Abattis Bioceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Abattis Bioceuticals upcoming earnings date is Oct 14, 2020, TBA Not Confirmed.

Abattis Bioceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Abattis Bioceuticals has paid 88.53K in taxes.

Abattis Bioceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Abattis Bioceuticals has $2.40M in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$832.69K billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Abattis Bioceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―